How much does GLP-1 weight-loss treatment cost in South Africa?

What does GLP-1 weight-loss treatment actually cost in South Africa? The medication alone runs between roughly R2,800 and R8,100 per month, depending on which GLP-1 a patient is prescribed and what dose they are on. But that figure is misleading on its own, because medication is only part of what supervised treatment costs, and most quoted prices don't include the rest.

This article is a reference for patients researching the cost of GLP-1 treatment before speaking to a clinician. It covers the medication prices in 2026, the realistic supporting costs of supervised treatment, how South African medical schemes treat GLP-1 claims, and how the long-term cost picture changes as patients move through dose escalation and maintenance.

The GLP-1 medications available in South Africa

Four GLP-1 medications are available to South African patients in 2026, and a fifth is registered but not yet sold locally.

Mounjaro (tirzepatide)

Mounjaro is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly and distributed in South Africa by Aspen Pharmacare under a licensing agreement signed in August 2023. Mounjaro launched locally in December 2024 for the treatment of type 2 diabetes, with the South African Health Products Regulatory Authority (SAHPRA) approving an additional indication for chronic weight management in October 2025. According to Aspen, it became the largest pharmaceutical product in South Africa by sales the following month.

Pricing varies by dose and by pharmacy dispensing fee. The 2.5mg starter dose costs roughly R2,800 per month, rising to around R4,600 at a 10mg maintenance dose. The highest vial strength sold in South Africa is 10mg. Patients on doses above this need two vials per week, with monthly costs running from R5,500 to R8,100.

Wegovy (semaglutide)

Wegovy is a GLP-1 receptor agonist containing semaglutide, manufactured by Novo Nordisk. It launched in South Africa in August 2025 and is registered locally for chronic weight management in adults.

Wegovy pricing ranges from roughly R1,900 per month at the 0.25mg starter dose to R3,750 at the 2.4mg maintenance dose, with intermediate doses falling between. Novo Nordisk has reduced Wegovy pricing twice since its August 2025 launch in response to competitive pressure from tirzepatide, with the most recent reduction in March 2026. A higher-dose 7.2mg Wegovy formulation has launched in some international markets but is not yet available in South Africa.

Ozempic (semaglutide)

Ozempic is a GLP-1 receptor agonist containing semaglutide, manufactured by Novo Nordisk. It is registered in South Africa only for the treatment of type 2 diabetes, but is widely prescribed off-label for weight loss.

Ozempic pricing ranges from roughly R1,700 per month at the 0.25mg/0.5mg starter pen to around R3,200 at a 1mg weekly maintenance dose, with each pen lasting four weeks. Because the 2mg single-strength pen sold in some international markets is not yet available locally, patients on a 2mg weekly dose need two of the lower-strength pens, bringing monthly costs to between R5,400 and R6,200.

Saxenda (liraglutide)

Saxenda is a GLP-1 receptor agonist containing liraglutide, manufactured by Novo Nordisk. It is administered as a daily subcutaneous injection, and was the first GLP-1 registered for chronic weight management in South Africa, predating both Wegovy and Mounjaro's weight-loss indication.

Saxenda is dispensed in boxes of three pens, priced at around R2,727 per box. At the standard maintenance dose of 3mg per day, patients use roughly five pens per month, bringing the monthly cost to about R4,600. Saxenda's daily injection schedule has led to declining uptake as weekly alternatives have become available, with Discovery Health reporting a 69% drop in chronic-illness claims for liraglutide between 2021 and 2024.

Rybelsus (oral semaglutide)

Rybelsus is an oral tablet formulation of semaglutide manufactured by Novo Nordisk. It was registered by SAHPRA in 2024 but has not yet been launched commercially in South Africa. Novo Nordisk has not publicly announced launch timing.

Other GLP-1s registered for diabetes only

Three further GLP-1 receptor agonists are registered in South Africa for type 2 diabetes but not for weight management: Trulicity (dulaglutide), Victoza (liraglutide at diabetes-level dosing), and Soliqua (lixisenatide combined with insulin glargine). They are sometimes prescribed off-label for weight loss, but are less effective for that purpose than the medications above.

The full cost of supervised treatment

Patients who price GLP-1 treatment by the medication alone consistently underestimate the real cost. Over the first six months of supervised treatment, the medication accounts for roughly 55 to 65 percent of total spend. The other 35 to 45 percent covers baseline investigations, clinical consultations, ongoing supervision, and supporting items. None of these are optional in a safely supervised programme.

Baseline investigations

Pre-treatment bloodwork is clinically indicated before initiating any GLP-1. The standard panel costs approximately R2,800–R3,100 at major SA pathology labs and typically includes HbA1c, fasting glucose, a full lipogram, urea/creatinine/electrolytes, liver function tests, and TSH. Patients who pay cash on the day usually qualify for a 15–20 percent discount, bringing the total to around R2,300–R2,500.

Some clinicians add ferritin, vitamin D, or fasting insulin, each costing around R300. Repeat bloodwork at the three-month and six-month marks adds R1,500 to R2,500 per round.

Consultations

Initial consultations for GLP-1 treatment range from around R500 at a standard GP to R1,700 at a dedicated weight-management programme. The wider range reflects how much time the consultation actually takes. A five-minute prescription discussion costs less than a 45-minute clinical assessment, and the more thorough version is what safe supervised treatment requires. Follow-up consultations run R400 to R900, with most six-month treatment plans including three to four of them.

Dietetic input

Dietetic input during GLP-1 treatment does specific clinical work. It protects lean muscle mass as weight comes off, supports adequate protein and micronutrients while appetite is suppressed, manages the gastrointestinal side effects most patients experience in the first few months, and builds the habits that keep the weight off after treatment ends.

Dietitian fees in South Africa generally follow Board of Healthcare Funders rates. An initial consultation, which typically includes a full eating-pattern assessment and an individual plan, costs R900 to R1,600. Follow-ups run R550 to R900. Across the first six months of supervised treatment, most patients have one initial consultation and four to six follow-ups, totalling roughly R3,500 to R6,500.

Supporting items

GLP-1 pens are dispensed without injection needles or sharps disposal containers, and patients buy both separately. A box of 100 NovoFine 32G x 4mm pen needles costs approximately R400 to R800 and lasts about two years on a weekly medication, or three months on Saxenda. Sharps containers add R50 to R150.

Many patients experience gastrointestinal side effects in the first few months of treatment, particularly nausea, reflux, and constipation. Managing these symptoms typically requires R500 to R1,500 in over-the-counter medication across the early months.

Most patients benefit from protein supplementation during active weight loss, because reduced appetite makes it hard to hit the protein targets that protect lean muscle mass. A six-month supply of whey or plant-based protein costs approximately R2,600 to R4,500.

Optional investigations

Some clinical protocols include body composition tracking (via InBody or DEXA scan) to monitor the ratio of fat to lean muscle mass during weight loss. Pricing varies widely: R200–R350 per InBody scan, R900–R1,500 per DEXA. A baseline and three-month follow-up adds R400 to R3,000.

Dose escalation and the long-term cost picture

Patients don't start GLP-1 treatment at the maintenance dose. The dose is titrated up over several months, both to let the body adapt to the medication and to manage side effects. This means monthly cost rises as treatment progresses, sometimes significantly.

Mounjaro

On Mounjaro, monthly cost rises from around R2,800 at the 2.5mg starter dose to R4,600 at the 10mg maintenance dose over the first four months of treatment, climbing in steps as the dose escalates. Patients who progress to doses above 10mg pay R5,500 to R8,100 because they need two vials per week. The highest single-vial strength sold in South Africa is 10mg.

Wegovy

Wegovy follows a 16-week titration from 0.25mg to the 2.4mg maintenance dose. Monthly cost rises from around R1,900 at the starter dose to R3,750 at maintenance, with intermediate doses falling between.

Ozempic

Ozempic, when prescribed off-label for weight loss, follows the same titration pattern used for type 2 diabetes. Monthly cost rises from around R1,700 at the 0.25mg/0.5mg starter pen to R3,200 at a 1mg weekly dose, the dose most commonly used for sustained weight loss in off-label practice. Patients on a 2mg weekly dose pay R5,400 to R6,200 because they need two of the lower-strength pens.

Saxenda

Saxenda is titrated daily over five weeks, increasing in 0.6mg increments from 0.6mg to the 3mg maintenance dose. The titration period is shorter than the weekly medications, but the daily injection means cost is consistent from the maintenance dose onwards: about R4,600 per month.

The 18-month cost picture

Across 18 months of supervised treatment, total cost depends on which medication a patient is on and what maintenance dose they reach. A patient on Mounjaro at a 10mg maintenance dose typically spends R110,000 to R155,000 over 18 months, of which medication accounts for roughly R79,000 and supervision, bloodwork, dietetic input, and supporting items make up the rest. A patient on Wegovy at the 2.4mg maintenance dose typically spends R95,000 to R125,000 over the same period. Ozempic falls below the Wegovy range; Saxenda sits roughly between the two.

What happens when treatment stops

GLP-1 treatment is increasingly understood as long-term care rather than a short course. When patients stop without a structured maintenance plan, most regain a substantial portion of the weight they lost. This means the 18-month cost figures above represent the start of an ongoing commitment, not the total. Lower-dose maintenance can reduce this commitment significantly: a patient maintaining weight on 5mg Mounjaro pays roughly half the monthly cost of a patient on 10mg.

For a full treatment of why regain happens and how to maintain results long-term, see our companion articles: Weight regain after stopping Ozempic, Wegovy or Mounjaro and Coming off Ozempic, Wegovy or Mounjaro without losing the result.

Medical aid coverage in South Africa

South African medical schemes are governed by the Medical Schemes Act 131 of 1998, which requires all schemes to cover a defined set of Prescribed Minimum Benefit (PMB) conditions. These cover 271 specific diagnoses and treatments, and 26 chronic conditions on the Chronic Disease List (CDL). Obesity is not classified as a PMB and is not on the CDL, but type 2 diabetes is.

Medical schemes are not required to fund GLP-1 medications prescribed for weight management. They are required to fund GLP-1 medications prescribed for type 2 diabetes, provided the patient meets the scheme's clinical criteria.

How major schemes treat GLP-1 claims

Discovery Health funds GLP-1 medications for members registered with type 2 diabetes on most plans (excluding KeyCare). If the member meets Discovery's clinical criteria, the medication is paid from the Chronic Illness Benefit. If not, it's paid from the member's day-to-day benefits. For obesity, Discovery only funds Saxenda (the one GLP-1 registered for weight management in SA), and only from day-to-day benefits.

Momentum Health Solutions funds GLP-1 medications as part of its diabetes chronic benefit, where the member meets clinical criteria. Wegovy and Mounjaro prescribed for weight loss are not covered. Other major schemes (Bonitas, Fedhealth, Medshield, Profmed, Bestmed, Polmed) apply broadly similar rules.

The diabetes diagnostic threshold

Overweight patients who haven't had recent bloodwork are sometimes already in early type 2 diabetes territory without knowing it. That diagnosis changes medical aid funding options entirely, since type 2 diabetes is covered under chronic benefits while obesity is not. The relevant thresholds: type 2 diabetes is diagnosed at an HbA1c of 6.5% or above, with prediabetes defined between 5.7% and 6.4%.

Practical considerations

Several practical details affect how GLP-1 claims are processed. The diagnostic code on the prescription matters most. A type 2 diabetes code (E11.9) opens chronic benefit pathways, while an obesity code (E66.x) does not. Most schemes also require chronic medication to be filled at a Designated Service Provider (DSP), with around a 20 percent co-payment on claims filled elsewhere. For borderline cases, a motivation letter from the prescribing doctor referencing BMI, comorbidities, and prior weight-loss attempts can support approval, but the letter is generally only provided when the patient requests it.

Some medical aid plans include an above-threshold benefit. Once a member's day-to-day spend has exceeded the scheme's threshold, additional outpatient medication is funded by the scheme rather than the member. Patients on chronic medication often reach this threshold mid-year.

Gap cover insurance does not cover outpatient chronic medication, including GLP-1 medications for weight management.

Unregulated and counterfeit products in the South African market

Cost pressure has produced a parallel market in unregistered, counterfeit, and compounded GLP-1 products. These are widely advertised on social media, sold through informal telehealth channels, and sometimes offered by pharmacies operating outside SAHPRA's regulatory framework. The prices are often dramatically lower than the registered products covered above, but the safety problems are serious.

The most serious safety problem starts with the ingredient itself. SAHPRA has stated that compounded products in South Africa frequently contain salt forms of semaglutide (such as semaglutide sodium or semaglutide acetate). These salt forms are not the active ingredient in the registered product and have not been assessed by SAHPRA for safety, quality, or efficacy.

Semaglutide and tirzepatide are both under patent in South Africa, and no manufacturer besides Novo Nordisk and Aspen (which holds the exclusive licence for tirzepatide) is legally authorised to produce or import them. Compounded products containing these active ingredients are therefore unlawful under the Medicines and Related Substances Act.

Enforcement against the unregistered market takes several forms. Novo Nordisk has applied for an interdict against Idexis Pharmaceuticals (trading as Sentra Pharmacy) in the Gauteng High Court relating to the supply of compounded semaglutide; the matter remains before the courts. South African port authorities have intercepted unauthorised shipments of semaglutide and tirzepatide imported from China, in some cases concealed within shipments of unrelated consumer goods.

In February 2025, the South African Police Service conducted a takedown operation in Pretoria targeting an online drug syndicate. The operation resulted in the arrest of six individuals and the seizure of counterfeit products including pens marketed as "Izempic," prefilled tirzepatide pens, retatrutide (a GLP-1/GIP/glucagon triple agonist still in clinical trials and not approved anywhere), and a product sold as a "fat burner" that was identified on forensic analysis as containing dimethylphenethylamine, a methamphetamine isomer.

Even when the product is what it claims to be, the picture is complicated by two further risks. Adverse events have been documented in compounded products, and patient-imported medication carries degradation risks from temperature exposure.

Documented safety concerns with compounded products

Most adverse-event data on compounded GLP-1 products comes from the United States, where the FDA tracks these incidents more systematically than SA does. As of March 2024, the FDA recorded 442 cases of adverse events linked to compounded semaglutide products. Of these, 319 were serious, 99 involved hospitalisation, and 7 involved death. Novo Nordisk has since put the death toll closer to 10. The FDA has also documented dosing errors from multi-dose vials, with patients self-administering doses 5 to 20 times higher than intended due to confusion converting between milligrams, millilitres, and insulin syringe units.

Patient-imported medication

Some patients buy GLP-1 medication overseas where prices are lower and bring it back to South Africa themselves. The challenge is that semaglutide and tirzepatide need to stay refrigerated between 2°C and 8°C, and medication transported in checked luggage or carried at ambient temperature for several hours can degrade. The resulting loss of potency can't be checked by looking at the pen, which means a patient may end up using a less effective product without realising it.

How to approach the decision

For a patient considering GLP-1 treatment, the sequence below is the standard approach.

Step 1: clinical suitability

The first step is to confirm GLP-1 treatment is medically indicated. The standard criteria are a body mass index (BMI) of 30 or above, or a BMI of 27 or above combined with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, or fatty liver disease.

Contraindications include a personal or family history of medullary thyroid carcinoma or MEN-2, severe gastroparesis, a history of severe pancreatitis, current or planned pregnancy within four weeks of starting treatment, and breastfeeding.

Step 2: baseline investigations

A full baseline blood panel is needed before starting treatment. The standard panel includes HbA1c, fasting glucose, lipogram, urea, creatinine and electrolytes, liver function tests, and TSH. It does two things. It identifies whether the patient meets diagnostic criteria for type 2 diabetes, which changes medical aid funding options, and it rules out contraindications.

Step 3: medical aid funding

Once clinical suitability is confirmed, the next step is contacting the medical scheme directly to confirm what they will cover. The most useful questions are whether the scheme funds GLP-1 medications under its Chronic Illness Benefit for type 2 diabetes, whether Saxenda is covered for weight management under day-to-day benefits, what the above-threshold benefit threshold is and when it kicks in, and which pharmacy the scheme designates for chronic medication.

Step 4: full treatment cost

The realistic 18-month cost of supervised GLP-1 treatment in South Africa is roughly R110,000 to R155,000 on Mounjaro at a 10mg maintenance dose, and R95,000 to R125,000 on Wegovy at the 2.4mg maintenance dose. These are household budget commitments over the full treatment period, not monthly costs.

Step 5: the supervised programme model

Supervised GLP-1 treatment typically includes a prescribing clinician, dietetic input, clinical follow-up, and structured behavioural support. Programmes differ in what they offer. Useful questions when comparing them are the qualifications of the clinical team, how side effects are managed between scheduled consultations, how dose is adjusted over time, what the plan is for ending treatment, and which licensed pharmacy dispenses the medication.